Financial Performance - The company's revenue for Q1 2022 was ¥120,451,245.21, a decrease of 15.07% compared to ¥141,827,415.71 in the same period last year[4] - Net profit attributable to shareholders was ¥13,044,337.80, down 14.62% from ¥15,277,393.73 year-on-year[4] - Basic and diluted earnings per share decreased by 38.89% to ¥0.11 from ¥0.18 in the same period last year[4] - Operating profit for Q1 2022 was CNY 14,005,079.72, a decline of 20.06% from CNY 17,650,222.77 in Q1 2021[18] - Net profit for Q1 2022 was CNY 12,776,354.19, down 15.88% from CNY 15,128,006.12 in Q1 2021[19] - Total operating costs for Q1 2022 were CNY 108,873,562.70, down 11.51% from CNY 123,053,088.90 in Q1 2021[18] Cash Flow - The net cash flow from operating activities was -¥36,560,040.95, a decline of 362.86% compared to ¥13,908,393.23 in the previous year[11] - Cash flow from operating activities showed a net outflow of CNY -36,560,040.95, compared to a net inflow of CNY 13,908,393.23 in Q1 2021[21] - The net cash flow from financing activities surged by 13,430.23% to ¥112,884,495.99, primarily due to increased bank financing[11] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 192,590,038.62, an increase from CNY 35,235,534.16 at the end of Q1 2021[21] - The company reported cash and cash equivalents of ¥200,331,867.65, down from ¥209,914,096.15[15] Assets and Liabilities - Total assets increased by 9.86% to ¥1,330,717,680.91 from ¥1,211,243,283.36 at the end of the previous year[4] - Total current assets amount to ¥890,504,289.46, an increase from ¥858,256,693.11 at the beginning of the year[15] - Total non-current assets are ¥440,213,391.45, up from ¥352,986,590.25 at the start of the year[16] - Total liabilities amount to ¥473,326,097.90, increasing from ¥382,828,054.54 at the start of the year[16] - Total equity attributable to shareholders of the parent company is ¥820,097,355.16, up from ¥807,053,017.36[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,064[13] - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares[13] Research and Development - Research and development expenses rose by 35.13% to ¥8,891,743.44 from ¥6,580,076.26 year-on-year, indicating increased investment in R&D[10] - Research and development expenses increased to CNY 8,891,743.44, up 35.29% from CNY 6,580,076.26 in Q1 2021[18] Tax and Fees - The company experienced a 87.17% decrease in tax and additional fees, amounting to ¥64,925.30 compared to ¥505,861.19 in the previous year[10] - The company reported a significant increase in tax refunds received, totaling CNY 3,155,809.99 compared to CNY 567,625.83 in Q1 2021[21] Borrowings and Investments - The company reported a significant increase in short-term borrowings, rising by 59.01% to ¥228,041,000.00 from ¥143,410,960.00[9] - The company’s long-term equity investments increased by 99.63% to ¥28,889,852.57, reflecting additional investments in joint ventures[8]
共同药业(300966) - 2022 Q1 - 季度财报